Abstract | BACKGROUND: METHODS: There were 25 male astronauts who were randomized into 2 groups: placebo (n = 18) and fludrocortisone (n = 7), and participated in stand tests 10 d before launch and 2-4 h after landing. Subjects took either 0.3 mg fludrocortisone or placebo orally 7 h prior to landing. Supine plasma and red cell volumes, supine and standing HR, arterial pressure, aortic outflow, and plasma norepinephrine and epinephrine were measured. RESULTS: On landing day, 2 of 18 in the placebo group and 1 of 7 in the fludrocortisone group became presyncopal (chi2 = 0.015, p = 0.90). Plasma volumes were significantly decreased after flight in the placebo group, but not in the fludrocortisone group. During postflight stand tests, standing plasma norepinephrine was significantly less in the fludrocortisone group compared with the placebo group. CONCLUSIONS:
|
Authors | Shang-Jin Shi, Donna A South, Janice V Meck |
Journal | Aviation, space, and environmental medicine
(Aviat Space Environ Med)
Vol. 75
Issue 3
Pg. 235-9
(Mar 2004)
ISSN: 0095-6562 [Print] United States |
PMID | 15018291
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, U.S. Gov't, Non-P.H.S.)
|
Chemical References |
- Anti-Inflammatory Agents
- Fludrocortisone
|
Topics |
- Adult
- Analysis of Variance
- Anti-Inflammatory Agents
(therapeutic use)
- Astronauts
- Fludrocortisone
(therapeutic use)
- Hemodynamics
(drug effects, physiology)
- Humans
- Hypotension, Orthostatic
(prevention & control)
- Hypovolemia
(prevention & control)
- Male
- Space Flight
- Sympathetic Nervous System
(physiology)
- Syncope
(prevention & control)
|